Drug intelligence / Profile preview

erlotinib + trastuzumab

Development stage: Preclinical
Lead developer: Astellas Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

Erlotinib + trastuzumab is a combination therapy that pairs two targeted cancer medications. Erlotinib is an EGFR tyrosine kinase inhibitor that blocks cell signaling pathways by binding to the ATP binding site of the EGFR receptor. Trastuzumab is a humanized monoclonal antibody that targets the HER2 receptor, preventing receptor dimerization and downstream signaling. The combination has shown potential benefits in treating cancers with EGFR mutations that also express HER2, as HER2 expression has been associated with resistance to EGFR-TKI therapy.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on erlotinib + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + trastuzumab.

Explore the full profile